Kronos Bio Director Reports Zero Holdings After $0.57-per-Share Takeover
Rhea-AI Filing Summary
Form 4 filing overview for Kronos Bio, Inc. (KRON)
The filing details the disposition of four tranches of stock options held by director Roshawn A. Blunt on 20 June 2025. The options, with exercise prices of $17.10, $3.53, $1.48 and $0.95, were cancelled or exchanged in connection with the closing of Kronos Bio’s merger with Concentra Biosciences LLC.
- Merger consideration for common shareholders: $0.57 per share in cash plus one contingent value right (CVR).
- Pursuant to the merger agreement, all unexercised options became fully vested immediately prior to the effective time.
- If an option’s exercise price was higher than the $0.57 cash amount, it was cancelled for no consideration; otherwise, the holder received the cash spread plus one CVR per underlying share.
- All four option grants had exercise prices above $0.57, resulting in no economic value to the reporting person. Post-transaction, Blunt reports zero derivative securities beneficially owned.
- The tender offer and subsequent merger were completed on 18 June 2025; the Form 4 documents changes dated 20 June 2025.
Because the merger converts Kronos Bio into a wholly-owned subsidiary of Concentra, this filing also serves as notice that the director is no longer subject to Section 16 reporting.
Positive
- None.
Negative
- None.
Insights
TL;DR: Insider options cancelled; no value due to $0.57 cash merger price versus higher strikes.
The Form 4 confirms completion of Concentra’s acquisition of Kronos Bio. For investors, the key takeaway is that all outstanding options with strikes ≥ $0.95 were out-of-the-money relative to the $0.57 cash consideration and therefore cancelled. This signals no additional dilution post-merger and illustrates the modest recovery Kronos shareholders received. The filing is largely administrative—documenting the director’s exit from beneficial ownership—yet it underscores the low ultimate valuation achieved in the sale. From a market-impact perspective, news of the merger was previously disclosed; today’s Form 4 merely finalises insider holdings, rendering it not materially price-moving.
TL;DR: Filing formalises Section 16 exit and option cancellation under merger terms.
The document evidences proper compliance with Section 16(a) following the closing of the Kronos-Concentra merger. By cancelling unexercised options or exchanging them for zero consideration, the company eliminates potential overhang and aligns with the merger agreement’s treatment of equity awards. The director’s ownership now stands at zero; consequently, the ‘check-off’ indicates she will no longer be a reporting person. Governance-wise, this clears outstanding insider equity and supports the transition to private ownership. No red flags appear; the mechanics mirror standard practice in cash-plus-CVR take-outs.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Disposition | Stock Option (Right to Buy) | 41,200 | $0.00 | -- |
| Disposition | Stock Option (Right to Buy) | 34,000 | $0.00 | -- |
| Disposition | Stock Option (Right to Buy) | 34,000 | $0.00 | -- |
| Disposition | Stock Option (Right to Buy) | 34,000 | $0.00 | -- |
Footnotes (1)
- Disposed of pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of May 1, 2025, by and among Kronos Bio, Inc. (the "Issuer"), Concentra Biosciences, LLC ("Parent") and Concentra Merger Sub IV, Inc., a wholly owned subsidiary of Parent ("Merger Sub"). On June 18, 2025, Parent and Merger Sub completed a tender offer pursuant to the terms of the Merger Agreement for all outstanding shares of common stock of the Issuer (each, a "Share") for an offer price of (i) $0.57 per Share in cash (the "Cash Amount"), and (ii) one non-transferable contractual contingent value right (each, a "CVR"), subject to and in accordance with the terms of the Contingent Value Rights Agreement (the "CVR Agreement"), in each case, without interest, and subject to any applicable withholding taxes (the Cash Amount plus one CVR, collectively, the "Offer Price").[continues to Footnote 2] [continues from Footnote 1] Merger Sub thereafter merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent (the "Merger"). As of immediately prior to and conditioned upon the effective time of the effective time of the Merger, pursuant to the Merger Agreement, each outstanding option to purchase Shares (each, an "Option") became fully vested and exercisable, and to the extent not exercised prior to the effective time of the Merger, was cancelled and converted into the right to receive (a) an amount in cash (without interest and subject to deduction for any required withholding tax) equal to the product of (1) the excess, if any, of the Cash Amount over the exercise price per share of each such Option and (2) the number of Shares underlying such Option immediately prior to the effective time of the Merger [continues to Footnote 3] [continues from Footnote 2] and (b) one CVR in respect of each Share underlying such Option; provided, however, that if the exercise price per Share of any Option was equal to or greater than the Cash Amount that was then outstanding it was cancelled for no consideration.
